The Week in Cancer News: Prolonging Survival in Pancreatic Cancer
A targeted therapy nearly doubles overall survival in metastatic pancreatic cancer, and the FDA approves a bladder cancer treatment.
Progress Against Cancer
A targeted therapy nearly doubles overall survival in metastatic pancreatic cancer, and the FDA approves a bladder cancer treatment.
At the AACR Annual Meeting 2026, Lillian Siu shared her research into cancer interception and assembled a panel to discuss targeted cancer prevention.
At the AACR Annual Meeting 2026, researchers discussed the use of vaccines and aspirin to prevent cancer in people with Lynch syndrome.
ACS colorectal cancer screening guideline now includes a blood-based test, and GLP-1 therapies may reduce risk for cancer progression.
In May, AACR's journals editors highlighted studies on CD28’s impact on CAR T-cell activity, the relationship between neurons and pancreatic cancer, and more.
An antibody-drug conjugate is approved to treat early-stage breast cancer, and preventive blood thinners linked to fewer blood clots.
In the CAR-PRISM clinical trial, the CAR T-cell therapy ciltacabtagene autoleucel showed promise for treating high-risk smoldering myeloma.
A recent analysis examined whether CYP2D6 metabolism influences tamoxifen response. The answer isn’t entirely clear.
The latest edition of our "From the Bench" series examines creative research approaches presented at the AACR Annual Meeting 2026 enabling new insights into cancer.
The FDA has approved fam-trastuzumab deruxtecan-nxki for neoadjuvant or adjuvant treatment of HER2-positive early-stage breast cancer. The U.S. Food and Drug Administration (FDA) approved fam-trastuzumab deruxtecan-nxki (T-DXd, Enhertu) for two indications in adult patients...
AACR Fellow Lewis C. Cantley, PhD, leads a national effort targeting triple-negative breast cancer and ovarian cancer with a novel drug combination.
Learn More